|
US7227010B2
(en)
*
|
1993-09-21 |
2007-06-05 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
US8153397B2
(en)
*
|
1993-09-21 |
2012-04-10 |
The United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
US7037680B2
(en)
*
|
1993-09-21 |
2006-05-02 |
The United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
EP0878552A1
(en)
*
|
1997-05-13 |
1998-11-18 |
Erasmus Universiteit Rotterdam |
Molecular detection of chromosome aberrations
|
|
JP2002513587A
(ja)
*
|
1998-05-04 |
2002-05-14 |
ダコ エー エス |
染色体異常を検出するための方法およびプローブ
|
|
US20060216313A1
(en)
*
|
1999-08-10 |
2006-09-28 |
Allergan, Inc. |
Methods for treating a stricture with a botulinum toxin
|
|
US7491799B2
(en)
*
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
|
US7691983B2
(en)
*
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
|
US20030219462A1
(en)
*
|
2000-07-21 |
2003-11-27 |
Allergan Sales, Inc |
Clostridial neurotoxin compositions and modified clostridial neurotoxins
|
|
US20040220100A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US20020127247A1
(en)
*
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
|
US7223577B2
(en)
|
2000-11-17 |
2007-05-29 |
Allergan, Inc. |
Post-translational modifications and Clostridial neurotoxins
|
|
US8022172B2
(en)
*
|
2001-08-28 |
2011-09-20 |
Allergan, Inc. |
Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
|
|
US7332567B2
(en)
*
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
|
US7374896B2
(en)
|
2001-08-28 |
2008-05-20 |
Allergan, Inc. |
GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
|
|
US20040115727A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Allergan, Inc., A Corporation |
Evolved clostridial toxins with altered protease specificity
|
|
US20040226556A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Deem Mark E. |
Apparatus for treating asthma using neurotoxin
|
|
US20050191321A1
(en)
*
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
|
JP2007527431A
(ja)
|
2004-03-03 |
2007-09-27 |
ルバンス セラピュティックス |
局所的診断及び治療用の輸送のための組成物及び方法
|
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
BRPI0508410B8
(pt)
*
|
2004-03-03 |
2021-05-25 |
Revance Therapeutics Inc |
composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
|
|
US20060024331A1
(en)
*
|
2004-08-02 |
2006-02-02 |
Ester Fernandez-Salas |
Toxin compounds with enhanced membrane translocation characteristics
|
|
US7399607B2
(en)
*
|
2004-09-22 |
2008-07-15 |
Allergan, Inc. |
Fluorescence polarization assays for determining clostridial toxin activity
|
|
WO2006068794A2
(en)
|
2004-11-22 |
2006-06-29 |
New York University |
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
|
|
ZA200707352B
(en)
|
2005-03-03 |
2009-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
AU2006227816B2
(en)
|
2005-03-15 |
2012-04-05 |
Allergan, Inc. |
Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
|
|
CN103126971A
(zh)
*
|
2005-11-17 |
2013-06-05 |
雷文斯治疗公司 |
减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
|
|
EP1834962A1
(de)
|
2006-03-15 |
2007-09-19 |
Biotecon Therapeutics GmbH |
PEGyliertes mutiertes Clostridium botulinum Toxin
|
|
WO2008105901A2
(en)
|
2006-07-11 |
2008-09-04 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
|
|
CN102988995A
(zh)
*
|
2006-12-29 |
2013-03-27 |
雷文斯治疗公司 |
用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
|
|
BRPI0720729A2
(pt)
*
|
2006-12-29 |
2014-04-08 |
Revance Therapeutics Inc |
Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
|
|
US8483831B1
(en)
|
2008-02-15 |
2013-07-09 |
Holaira, Inc. |
System and method for bronchial dilation
|
|
KR101719824B1
(ko)
|
2008-05-09 |
2017-04-04 |
호라이라 인코포레이티드 |
기관지나무 치료용 시스템, 어셈블리 및 방법
|
|
KR20110060903A
(ko)
|
2008-08-29 |
2011-06-08 |
메르츠 파마 게엠베하 운트 코. 카가아 |
지속성이 변경된 클로스트리듐 신경독
|
|
GB0903913D0
(en)
*
|
2009-03-06 |
2009-04-22 |
Medical Res Council |
Compositions and methods
|
|
KR101923847B1
(ko)
*
|
2009-03-13 |
2018-11-29 |
알러간, 인코포레이티드 |
면역 기반 재표적화된 엔도펩티다제 활성 검정
|
|
US20100303757A1
(en)
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
|
|
US20100303783A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
|
|
US20100303788A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
|
|
US20100303794A1
(en)
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
|
|
BRPI1014253A2
(pt)
*
|
2009-07-02 |
2016-04-12 |
Merz Pharma Gmbh & Co Kgaa |
polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
|
|
EP2464662A1
(en)
*
|
2009-08-12 |
2012-06-20 |
Medical Research Council |
Complexing system
|
|
EP2483666A1
(en)
|
2009-10-02 |
2012-08-08 |
Allergan, Inc. |
In vitro method of determining changes in a protein environment
|
|
EP2926757B1
(en)
|
2009-10-27 |
2023-01-25 |
Nuvaira, Inc. |
Delivery devices with coolable energy emitting assemblies
|
|
US8911439B2
(en)
|
2009-11-11 |
2014-12-16 |
Holaira, Inc. |
Non-invasive and minimally invasive denervation methods and systems for performing the same
|
|
AU2010319477A1
(en)
|
2009-11-11 |
2012-05-24 |
Holaira, Inc. |
Systems, apparatuses, and methods for treating tissue and controlling stenosis
|
|
SG181772A1
(en)
|
2009-12-16 |
2012-07-30 |
Allergan Inc |
Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
|
|
JP5956350B2
(ja)
|
2010-01-25 |
2016-07-27 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
単鎖タンパク質をそれらの２鎖形態に細胞内変換する方法
|
|
EP2528941A4
(en)
*
|
2010-01-25 |
2013-05-29 |
Univ New York |
FOR TRANSPORT STUDIES AND NEURONAL ADMINISTRATION, MANIPULATED RECOMBINANT DERIVATIVES FROM BOTULINUM NEUROTOXINES
|
|
US8916162B2
(en)
*
|
2010-02-20 |
2014-12-23 |
Alexey Gennadievich Zdanovsky |
Botulinum neurotoxin antigenic compositions and methods
|
|
EP2650003B1
(en)
|
2010-05-20 |
2016-07-27 |
Allergan, Inc. |
Degradable clostridial toxins
|
|
US20120251574A1
(en)
*
|
2011-03-28 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
|
|
WO2013017522A1
(en)
*
|
2011-08-04 |
2013-02-07 |
Merz Pharma Gmbh & Co. Kgaa |
Alteration of proteolytic cleavage of botulinum neurotoxins
|
|
BR112014011137A2
(pt)
*
|
2011-11-09 |
2018-06-12 |
Merz Pharma Gmbh & Co Kgaa |
polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
|
|
MX370929B
(es)
|
2012-10-28 |
2020-01-08 |
Revance Therapeutics Inc |
Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
|
|
US20150322118A1
(en)
*
|
2012-12-05 |
2015-11-12 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant clostridial neurotoxins with enhanced membrane localization
|
|
US9398933B2
(en)
|
2012-12-27 |
2016-07-26 |
Holaira, Inc. |
Methods for improving drug efficacy including a combination of drug administration and nerve modulation
|
|
US9315549B2
(en)
|
2013-01-28 |
2016-04-19 |
New York University |
Treatment methods using atoxic neurotoxin derivatives
|
|
GB201312317D0
(en)
*
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
|
HK1225744A1
(zh)
|
2013-07-30 |
2017-09-15 |
Merz Pharma Gmbh & Co. Kgaa |
制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
|
|
CN105683212B
(zh)
*
|
2013-08-21 |
2020-03-17 |
香港理工大学 |
高催化活性的基因改造梭菌属神经毒素
|
|
WO2015132004A1
(en)
|
2014-03-05 |
2015-09-11 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
|
US11897921B2
(en)
|
2014-12-09 |
2024-02-13 |
New York University |
Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
|
|
WO2016110662A1
(en)
|
2015-01-09 |
2016-07-14 |
Ipsen Bioinnovation Limited |
Cationic neurotoxins
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
|
GB201517450D0
(en)
|
2015-10-02 |
2015-11-18 |
Ipsen Biopharm Ltd |
Method
|
|
US11078472B2
(en)
|
2016-01-20 |
2021-08-03 |
Merz Pharma Gmbh & Co., Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
|
CN108463242A
(zh)
|
2016-03-02 |
2018-08-28 |
梅尔兹制药公司 |
包含肉毒杆菌毒素的组合物
|
|
GB201607901D0
(en)
|
2016-05-05 |
2016-06-22 |
Ipsen Biopharm Ltd |
Chimeric neurotoxins
|
|
TW201814045A
(zh)
|
2016-09-16 |
2018-04-16 |
英商艾普森生物製藥有限公司 |
製造雙鏈梭狀芽孢桿菌神經毒素之方法
|
|
JP7118055B2
(ja)
|
2016-09-29 |
2022-08-15 |
イプセン バイオファーム リミテッド |
ハイブリッド神経毒
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
|
|
EP3649143B1
(en)
|
2017-07-06 |
2022-08-31 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
|
US20200354706A1
(en)
|
2017-11-22 |
2020-11-12 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
WO2019243376A1
(en)
|
2018-06-18 |
2019-12-26 |
Ipsen Biopharm Limited |
Intramuscular injection of botulinum toxin for the treatment of vulvodynia
|
|
GB201815844D0
(en)
|
2018-09-28 |
2018-11-14 |
Ipsen Biopharm Ltd |
Therapeutic & comestic uses of botulinum neurotoxin serotype e
|
|
CA3111674A1
(en)
|
2018-09-28 |
2020-04-02 |
Ipsen Biopharm Limited |
Cell-based clostridal neurotoxin assays
|
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|
|
US12162912B2
(en)
|
2018-11-21 |
2024-12-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Proteins for blocking neurotransmitter release
|
|
GB201900621D0
(en)
|
2019-01-16 |
2019-03-06 |
Ipsen Biopharm Ltd |
Labelled polypeptides
|
|
GB201907016D0
(en)
|
2019-05-17 |
2019-07-03 |
Ipsen Biopharm Ltd |
Screening method to determine suitability for participation in a clinical trial
|
|
GB201914034D0
(en)
|
2019-09-30 |
2019-11-13 |
Ipsen Biopharm Ltd |
Treatment of neurological disorders
|
|
GB202001353D0
(en)
|
2020-01-31 |
2020-03-18 |
Ipsen Biopharm Ltd |
Treatment of skin conditions
|
|
GB202100566D0
(en)
|
2021-01-15 |
2021-03-03 |
Ipsen Biopharm Ltd |
Treatment of brain damage
|
|
GB202103372D0
(en)
|
2021-03-11 |
2021-04-28 |
Ipsen Biopharm Ltd |
Modified clostridial neurotoxins
|
|
GB202104294D0
(en)
|
2021-03-26 |
2021-05-12 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an exogenous activation loop
|
|
KR20230001260A
(ko)
*
|
2021-06-28 |
2023-01-04 |
(주)메디톡스 |
재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
|
|
GB202116795D0
(en)
|
2021-11-22 |
2022-01-05 |
Ipsen Biopharm Ltd |
Treatment of visceral pain
|
|
GB202214232D0
(en)
|
2022-09-28 |
2022-11-09 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising an activating exogenous protease cleavage site
|
|
GB202214229D0
(en)
|
2022-09-28 |
2022-11-09 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an activating endosomal protease cleavage site
|
|
CH720444A2
(de)
*
|
2023-01-20 |
2024-07-31 |
Abbvie Inc |
Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
|
|
GB202318884D0
(en)
|
2023-12-11 |
2024-01-24 |
Ipsen Biopharm Ltd |
Formulation
|